Evidence map›Paper›PMID 36370475›Full record

ArticleJournal of molecular and cellular cardiology2023

Signaling network model of cardiomyocyte morphological changes in familial cardiomyopathy.

Ali Khalilimeybodi, Muhammad Riaz, Stuart G Campbell, Jeffrey H Omens, Andrew D McCulloch, Yibing Qyang, Jeffrey J Saucerman

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular and cellular cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Striking the balance: Complexity, simplicity, and credibility in mathematical biology.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ali KhalilimeybodiDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, United States of America.
Muhammad RiazYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Stuart G CampbellDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Jeffrey H OmensDepartments of Bioengineering and Medicine, University of California, San Diego, La Jolla, CA, United States of America.
Andrew D McCullochDepartments of Bioengineering and Medicine, University of California, San Diego, La Jolla, CA, United States of America.
Yibing QyangYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; Yale Stem Cell Center, New Haven, CT, United States of America; Department of Pathology, Yale University, New Haven, CT, United States of America; Vascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, CT, United States of America.
Jeffrey J SaucermanDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA, United States of America; Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA, United States of America. Electronic address: jsaucerman@virginia.edu.
Yale University · USUniversity of California, San Diego · USUniversity of Virginia · US

Funding

The Cardiac Atlas ProjectR01HL121754 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MCCULLOCH, ANDREW D., OMENS, JEFFREY H. · 2014 to 2023
$5.0M
Systems Pharmacology Model of Cardiac HypertrophyR01HL162925 · NHLBI · UNIVERSITY OF VIRGINIA · PI SAUCERMAN, JEFFREY J., WOLF, MATTHEW J · 2022 to 2025
$3.1M
Computational and Experimental Modeling of Cardiomyocyte ProliferationR01HL160665 · NHLBI · UNIVERSITY OF VIRGINIA · PI SAUCERMAN, JEFFREY J., VAN BERLO, JOHANNES (JOP) · 2022 to 2025
$2.8M
Systems Biology of Hypertrophic Heart Disease from Molecular Pathways to Organ SystemR01HL137100 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MCCULLOCH, ANDREW D. · 2017 to 2020
$2.0M
Systems Pharmacology Model for Spatial Control of Cardiac FibrosisR01HL137755 · NHLBI · UNIVERSITY OF VIRGINIA · PI HOLMES, JEFFREY W, SAUCERMAN, JEFFREY J. · 2017 to 2020
$1.9M
Modulation of heart function by Muscle LIM protein-mediated mechanotransductionR01HL164783 · NHLBI · YALE UNIVERSITY · PI QYANG, YIBING · 2022 to 2025
$1.7M
NHLBI NIH HHS R01 HL121754NHLBI NIH HHS R01 HL137100NHLBI NIH HHS R01 HL137755NHLBI NIH HHS R01 HL160665NHLBI NIH HHS R01 HL162925NHLBI NIH HHS R01 HL164783
6 · The paper itself

Abstract

Familial cardiomyopathy is a precursor of heart failure and sudden cardiac death. Over the past several decades, researchers have discovered numerous gene mutations primarily in sarcomeric and cytoskeletal proteins causing two different disease phenotypes: hypertrophic (HCM) and dilated (DCM) cardiomyopathies. However, molecular mechanisms linking genotype to phenotype remain unclear. Here, we employ a systems approach by integrating experimental findings from preclinical studies (e.g., murine data) into a cohesive signaling network to scrutinize genotype to phenotype mechanisms. We developed an HCM/DCM signaling network model utilizing a logic-based differential equations approach and evaluated model performance in predicting experimental data from four contexts (HCM, DCM, pressure overload, and volume overload). The model has an overall prediction accuracy of 83.8%, with higher accuracy in the HCM context (90%) than DCM (75%). Global sensitivity analysis identifies key signaling reactions, with calcium-mediated myofilament force development and calcium-calmodulin kinase signaling ranking the highest. A structural revision analysis indicates potential missing interactions that primarily control calcium regulatory proteins, increasing model prediction accuracy. Combination pharmacotherapy analysis suggests that downregulation of signaling components such as calcium, titin and its associated proteins, growth factor receptors, ERK1/2, and PI3K-AKT could inhibit myocyte growth in HCM. In experiments with patient-specific iPSC-derived cardiomyocytes (MLP-W4R;MYH7-R723C iPSC-CMs), combined inhibition of ERK1/2 and PI3K-AKT rescued the HCM phenotype, as predicted by the model. In DCM, PI3K-AKT-NFAT downregulation combined with upregulation of Ras/ERK1/2 or titin or Gq protein could ameliorate cardiomyocyte morphology. The model results suggest that HCM mutations that increase active force through elevated calcium sensitivity could increase ERK activity and decrease eccentricity through parallel growth factors, Gq-mediated, and titin pathways. Moreover, the model simulated the influence of existing medications on cardiac growth in HCM and DCM contexts. This HCM/DCM signaling model demonstrates utility in investigating genotype to phenotype mechanisms in familial cardiomyopathy.

Indexed as

CardiomyopathiesCardiomyopathy, HypertrophicHeart FailureAnimalsCalciumConnectinMiceMyocytes, CardiacPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktCalciumConnectinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktCardiac growthDCMFamilial cardiomyopathyGenotype to phenotypeHCMInherited cardiomyopathyPatient-specific iPSC-CMsSignaling

Identifiers

PMID36370475
PMCPMC10230857
OpenAlexW4309198524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.